Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
V. Burgio
Observed name:
V., Burgio
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
ORCID:
0000-0002-0146-4136
Observed ORCID:
0000-0002-0146-4136
OpenAlex ID:
A5022008359
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
2025
·
P. Ciracì
, M.M. Germani
, et al.
·
Annals of Oncology
·
31
PDF
4O Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial
2025
·
P. Ciracì
, M.M. Germani
, et al.
·
Annals of Oncology
·
2
PDF
67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
2022
·
M. Persano
, M. Rimini
, et al.
·
Immuno-Oncology Technology
·
1
LBA32 Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomized PARERE trial by GONO
2025
·
M.M.M. Germani
, P. Ciracì
, et al.
·
Annals of Oncology
PDF
Supplementary Material for: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2023
·
M., Rimini
, M., Persano
, et al.
·
Figshare
65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
2022
·
M. Rimini
, A. Casadei Gardini
, et al.
·
Immuno-Oncology Technology
SO-3 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
2022
·
M. Rimini
, T. Macarulla
, et al.
·
Annals of Oncology
Supplementary Material for: REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study
2022
·
A., Casadei-Gardini
, M., Rimini
, et al.
·
Figshare
Show more works
View as search
Works count:
8
Citation count:
34
H-index:
2
I10-index:
1
Year
Topic
Type